Literature DB >> 2387316

Association of a particular amino acid sequence of the HLA-DR beta 1 chain with HTLV-I-associated myelopathy.

K Usuku1, M Nishizawa, K Matsuki, K Tokunaga, K Takahashi, N Eiraku, M Suehara, T Juji, M Osame, T Tabira.   

Abstract

Analyses of HLA-DRB1 gene using polymerase chain reaction and sequence-specific oligonucleotide probes reveal that the amino acid sequence Glu-Gln-Arg-Arg-Ala-Ala-Val at positions 69-75 of the third hypervariable region (HVR) of HLA-DR beta 1 chain is significantly associated with HTLV-I-associated myelopathy (HAM). Since the frequency of this sequence in HTLV-I carriers is almost the same as that in controls from Kagoshima (an endemic area of HTLV-I), this sequence may be related to susceptibility to HAM rather than to susceptibility to HTLV-I infection. Since this third HVR functions as putative antigen-binding sites and T cell recognition sites, the amino acid sequence of positions 68-73 was analyzed in detail. The analysis reveals that Gln70 and Arg71 are relevant to the occurrence of HAM.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387316     DOI: 10.1002/eji.1830200729

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

2.  HLA profile and HTLV-I associated myelopathy (HAM/TSP) in Natal, South Africa.

Authors:  A I Bhigjee; P L Bill; M G Hammond; I M Windsor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-04       Impact factor: 10.154

3.  Defective human T-cell lymphotropic virus type I (HTLV-I) provirus in 10 Chilean seronegative patients with tropical spastic paraparesis or HTLV-I-associated myelopathy.

Authors:  E Ramirez; L Cartier; M Rios; J Fernandez
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

4.  Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.

Authors:  B Kitze; K Usuku; Y Yamano; S Yashiki; M Nakamura; T Fujiyoshi; S Izumo; M Osame; S Sonoda
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

5.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  MRI-pathological correlate of brain lesions in a necropsy case of HTLV-I associated myelopathy.

Authors:  A Ogata; K Nagashima; K Tashiro; A Miyakawa; C Mikuni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

Review 7.  Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I.

Authors:  C R Bangham; S E Hall; K J Jeffery; A M Vine; A Witkover; M A Nowak; D Wodarz; K Usuku; M Osame
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

Review 8.  A Review of Pulmonary Toxicity of Electronic Cigarettes in the Context of Smoking: A Focus on Inflammation.

Authors:  Peter G Shields; Micah Berman; Theodore M Brasky; Jo L Freudenheim; Ewy Mathe; Joseph P McElroy; Min-Ae Song; Mark D Wewers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-22       Impact factor: 4.254

9.  HTLV-I infection and neurological disease in Rio de Janeiro.

Authors:  A de Q Araujo; A Ali; A Newell; A G Dalgleish; P Rudge
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

10.  Post-transplantation HTLV-1 myelopathy in three recipients from a single donor.

Authors:  J J Zarranz Imirizaldu; J C Gomez Esteban; I Rouco Axpe; T Perez Concha; F Velasco Juanes; I Allue Susaeta; J M Corral Carranceja
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.